Evidence suggests THCV, a minor cannabinoid found in the cannabis plant, may decrease appetite and up-regulate energy metabolism, offering unique therapeutics properties.
As its name suggests, THCV (Δ9-Tetrahydrocannabivarin) is similar to THC (Δ9-tetrahydrocannabinol) in molecular structure, however it provides a variety of pronounced – and altogether different – therapeutic effects.
THCV is a naturally occurring analog of THC. Unlike THC, which is psychoactive and an agonist at the CB1 and CB2 receptors, THCV is a non-psychoactive, neutral CB1 antagonist / reverse agonist and may act as agonist or antagonist at the CB2 receptors, depending on its dose.
In rodent studies, THCV decreases appetite, increases satiety, and up-regulates energy metabolism, making it a clinically useful remedy for weight loss and management of obesity and type 2 diabetic patients.
The distinctions between THCV and THC in terms of glycemic control, glucose metabolism, and energy regulation have been demonstrated in previous studies. Also, the effect of THCV on dyslipidemia and glycemic control in type 2 diabetics showed reduced fasting plasma glucose concentration when compared to a placebo group.
In contrast, THC is indicated in individuals with cachexia. However, the uniquely diverse properties of THCV provide neuroprotection, appetite suppression, glycemic control, and reduced side effects, and so on; therefore, making it a potential priority candidate for the development of clinically useful therapies in the future.
In the future we hope THCV could provide an optional platform for the treatment of life-threatening diseases.
The therapeutic benefits of the extracts from the plant Cannabis sativa L. and its subspecies (hemp, marijuana) have been extensively studied. Cannabidiol (CBD), Δ-9-tetrahydrocannabinol (THC) and Δ-9-tetrahydrocannabivarin (THCV) are the major components isolated from Cannabis sativa and have been reported extensively in modern literature.
THC is the primary psychoactive component of Cannabis sativa and its medicinal properties are attributed to its specific interaction with the endocannabinoid system (ECS) (Borgelt et al. 2013; McPartland et al. 2015; Chakrabarti et al. 2015). ECS consists of two types of endogenous G protein-coupled cannabinoid receptors (CB1 and CB2) that are located in the mammalian brain and throughout the central and peripheral nervous systems (Pertwee 2008; Solinas et al. 2008).
The EC system represents a major neuromodulatory system involved in the regulation of emotional responses, behavioral reactivity, and social interactions. Pathophysiologic manipulation of the ECS has been exploited as a key tool in the management of severe disease conditions of the central nervous system. For example, in recent years, elements of the ECS and its pathways have been explored as therapeutic measures for mitigating some central nervous system diseases such as Autism Spectrum Disorder (ASD) and epilepsy (Chakrabarti et al. 2015).
The endocannabinoid system is also responsible for the maintenance of energy homeostasis and the regulation of lipid and glucose metabolism (McPartland et al. 2015). In the same vein, molecular markers have been identified in the ECS membrane transporters (AM404) that could trigger autistic behavior when the cannabinoid receptors are activated (Chakrabarti et al. 2015).
THC produces various psychoactive effects by activation of the CB1 cannabinoid receptors in the brain, especially the basal ganglia, substantia nigra, globus pallidus, hippocampus, cerebellum, etc. These locations indicate that THC is involved in the modulation of memory, emotions, and movement.
Activation of the CB1 receptors leads to inhibition of adenylyl cyclase and blockade of voltage-operated calcium channels, which in turn suppresses neuronal excitability and inhibition of neurotransmission of serotonin (Pertwee 2008). Therefore, the therapeutic benefits of THC include the management of conditions associated with depression, Parkinson’s disease, Alzheimer’s disease, resistant childhood seizures, chronic pain, multiple sclerosis, convulsions, glaucoma, neuropathic pain and a variety of other conditions (Hill 2015; Grant et al. 2012).
Research efforts in cannabis have been intensified to develop several synthetic high-affinity analogs of CB1 cannabinoid receptor antagonists and inverse agonists as therapeutic drugs for the management of drug dependence, metabolic syndrome, and diabetes. Literature is replete with inverse agonists of the CB1 cannabinoid receptors that have been developed for the management of drug dependence, metabolic syndrome, type 2 diabetes and dyslipidemia (Brown 2007).
Rimonabant, a first-generation synthetic inverse agonist / selective antagonist of the CB1receptor, was approved in Europe in 2006 for the treatment of anorectic obesity (Bridgeman and Abazia 2017). This drug exerts its effect on the ECS by selectively blocking the CB1receptors; thus, reducing appetite and inducing hypophagia. In a randomized double-blind, rimonabant-placebo controlled trial; rimonabant produced a significant reduction in body weights of subjects from 2.6 to 6.3 kg relative to placebo among the groups taking 20 mg of rimonabant daily. HbA1C in obese patients decreased by 0.5–0.6% compared to metformin or sulphonylurea, and 0.8% reduction compared to 0.3% reduction in placebo group.
High-density lipoproptein cholesterol (HDL-C) also increased significantly by 22.3% compared with 13.4% in the placebo group while the level of triglycerides decreased in all trials by 6.8% compared with an increase of 8.3% in the placebo group (p < 0.0001). The levels of adiponectin, a protein hormone regulating glucose level and fatty acid breakdown in humans, increased significantly by 23% from the baseline in the 20 mg rimonabant group.
It was concluded that rimonabant is effective in controlling blood glucose levels and reducing weight in obese patients; however, it was withdrawn from the global market in 2008 due to increased incidences of nausea, upper respiratory tract infections, and serious psychiatric side effects including depression and suicide ideation (Buggy et al. 2011; Christopoulou and Kiortsis 2011; Le Foll et al. 2009).
This left a huge research gap as many pharmaceutical companies abandoned the development of inverse CB1 receptor agonists. It was opined that the development of novel compounds that are neutral antagonists of the CB1 receptor with selectivity for peripheral receptors may be of great value in obtaining similar metabolic results with little or no psychiatric adverse effects. Therefore, research in this area is continuous.
THCV is an inverse agonist / selective antagonist of the CB1 receptor, similar to rimonabant but it does not have the identified adverse effects of rimonabant. This short review discusses the potential therapeutic benefits of THCV, a naturally occurring analog of THC, in the management of obesity and type 2 diabetes, its potential side effects, and the mechanism of action within the ECS.
A narrative electronic literature search was performed using peer-reviewed articles published from January 1, 1970, until September 30, 2019. An article was selected if it included keywords such as Δ9-tetrahydrocannabivarin (THCV), Δ9-tetrahydrocannabinol (THC), Cannabis sativa (marijuana), obesity, body weight, metabolism, and diabetes. Articles were then reviewed and included based on the applicability to the topic.
THCV is a naturally occurring analog of THC. Unlike THC, which is psychoactive and an agonist at the CB1 and CB2 receptors, THCV is a non-psychoactive, neutral CB1 antagonist / reverse agonist and may act as agonist or antagonist at the CB2 receptors depending on its dose. It is thought that THCV prevents the psychological effects of THC however; the mechanism by which THCV antagonizes the effect of THC is unknown. Also unlike THC, THCV produces hypophagic effects in both fasted and non-fasted mice (Riedel et al. 2009). It follows that THCV has great potential for the management of obesity.
The effect of THCV in diet-induced obesity (DIO) and genetic obesity (GO) was evaluated in mice (4 mice per group) using two orally administered dose ranges of THCV stock solution. The solution was appropriately diluted to the required strength using sesame seed oil, for the DIO group at 0.3–12.5 mg/kg twice daily for 30 days and 0.1–12.5 mg/kg once daily for 45 days. One pilot study of 0.3–3 mg/kg per oral once daily; and one full dose range of 0.1–12.5 mg/kg once daily for 30 days in obese mice (Wargent et al. 2013) were also conducted.
The results were compared to a potent CB1 inverse agonist (AM251) administered per oral at 10 mg/kg once daily or 5 mg/kg twice daily as a positive control. Both doses of AM251 reduced mice’s body weight significantly by greater than 8 g (p < 0.001) whereas, THCV did not have any significant effect on the body weight at any of the doses used in the study. Similarly, AM251 decreased the total food intake over the first 10 days of the study, but THCV had no significant effect on the mice’s food intake throughout the study. Neither AM251 nor THCV affected water intake. However, there was a significant reduction in the fat contents by both AM251 (26.4%) and THCV (31.1%) compared to the control (42.1%).
There was generally no statistically significant effect on these parameters in the genetically obese mice. It was concluded that similar to AM251, THCV has a high affinity for CB1 receptors and high brain penetration, producing some metabolically beneficial effects typical of CB1 receptor inverse agonist in two different mouse models of obesity. The strongest effect was on plasma glucose and insulin levels, as well as liver triglycerides. It was opined that THCV may be useful for the treatment of metabolic syndrome and/or type 2 diabetes, either alone or as an adjuvant treatment with other therapeutic options.
Since ECS modulates appetite, food consumption and feeding behavior in animals and humans (Solinas et al. 2008) the acute use of THC, a partial agonist of the CB1 receptors, is classically associated with acute appetite-enhancing effects, as well as an increase in the frequency of sucrose ingestion (Jarrett et al. 2005). When THC was administered to rats before the intraoral infusion of sucrose solution, it was noted that THC increased the frequency of sucrose ingestion at 30 and 60 min and particularly, increased palatability at the 120-min interval (Jarrett et al. 2005). Conversely, rimonabant, a CB1 antagonist that is similar to THCV, resulted in the reversal of the enhanced frequency of sucrose ingestion and increased palatability (Jarrett et al. 2005).
In a similar report, THCV, a neutral antagonist of the CB1 receptors resulted in decreased food intake and body weight reduction in mice models; thus, exerting an anti-obesity effect in mouse models by food aversion (Wargent et al. 2013; Tudge et al. 2015). The metabolic effect of THCV can be explained by its interaction with the transient receptor potential cation channel subfamily V member 1 (TRPV1), also known as the capsaicin receptor (Riedel et al. 2009).
Unlike THC, THCV is observed to induce a therapeutic metabolic effect by restoring insulin sensitivity in obese mice models and interacting with the TRPV1 channels (De Petrocellis et al. 2011). THCV has been shown to restore insulin sensitivity in diet-induced obese mice models and reducing obesity by modulating the metabolic processes.
The chemical structures of two of the most abundant phytocannabinoids in Cannabis sativa L. are highlighted in Fig. 1: THC (a), THCV (b). These phytocannabinoids share some similar structural features that include a dibenzopyran ring and a hydrophobic alkyl chain, but each interacts with the ECS in a slightly different manner (Gill et al. 1970; Jager and Witkamp 2014). Existing in continuous dynamic equilibrium with each other, endocannabinoids are a part of a class of structurally related amides, esters, and ethers of fatty acids (Gill et al. 1970). Although each of these compounds has a slightly different molecular structure, biosynthesis, and physicochemical properties, they all interact with the ECS to maintain homeostasis and regulate lipid and glucose metabolism (Wargent et al. 2013; Jarrett et al. 2005).
For instance, THC and CBD are biosynthesized as tetrahydrocannabinolic acid (THC-A) and cannabidiolic acid (CBD-A) respectively from a common precursor cannabigerolic acid (CBG). These phytocannabinoids are inactive in their natural acidic states but are converted to their respective therapeutically active forms by decarboxylation process when heated. Although they are from the same precursor, THC acts as an agonist at the cannabinoid receptors and results in an increased lipid and glucose intake (McPartland et al. 2015; Jarrett et al. 2005; Jager and Witkamp 2014), whereas THCV exhibits antagonistic activities at the cannabinoid receptors (Thomas et al. 2005).
Studies using mice models have indicated dose-dependent therapeutic effects (Jadoon et al. 2016). At low intravenous doses (0.1, 0.3, 1.0 and/or 3 mg/kg), the plant-derived THCV and its synthetic analogs (O-4394 and O-4395) show antagonism at the cannabinoid receptors by reversing some of the effects of THC, such as THC-induced antinociception and hypothermia (Pertwee et al. 2007).
THC activates both peripheral and central CB1 receptors (Muniyappa et al. 2013) when administered alone. At higher doses, both O-4394 and O-4395 exhibit agonistic effects at the cannabinoid receptors by precipitating hypothermia (above 3 mg/kg) and antinociception (above 10 mg/kg) (Pertwee et al. 2007). The cannabinoid receptors and their ligands have been implicated in feeding and metabolic control regulations (Cluny et al. 2015; Ravinet-Trillou et al. 2004) providing a potential therapeutic benefit for the treatment of type 2 diabetes in the human population.
A significant increase in body weight (24%) and adiposity (60%) in CB1 +/+ mice compared to the CB1 −/− mice has been reported when both groups were fed with standard diet containing 3.5 kcal/g and 14.5% of energy as fat (Ravinet-Trillou et al. 2004). However, when both types of mice were fed with a high-fat obesity-prone diet containing 4.9 kcal/g and 49% of energy as fat, CB1 −/− mice did not develop obesity in contrast to the CB1 +/+ mice in spite of the similar energy intake.
This suggests an improved metabolic regulation in the CB1 −/− mice (Ravinet-Trillou et al. 2004). In another study, fasting plasma glucose levels and oral glucose tolerance test (OGTT) improved in mice with diet-induced obesity when plant-derived THCV was administered twice daily (Wargent et al. 2013).
Administration of intraperitoneal plant-derived THCV in rodents resulted in weight loss, reduced food intake, reduced body fat content, increased energy expenditure, rapid insulin response to OGTT (Wargent et al. 2013), and reduced liver triglycerides (Ravinet-Trillou et al. 2004; Englund et al. 2015).
Similar to the rimonabant human clinical trials mentioned above, the selective CB1 receptor antagonist rimonabant, exhibited potent anti-obesity properties in CB1 (+/+) obese mice leading to leanness and hypophagia (Wargent et al. 2013; Ravinet-Trillou et al. 2004). In Zucker rats, rimonabant reduced the levels of plasma triglycerides, free fatty acids, total cholesterol, and increased the levels of high-density lipoprotein/low-density lipoprotein (HDL/LDL) ratio (Thomas et al. 2005).
Similar effects on lipid profiles were observed when a high dose of the plant-derived THCV (12.5 mg/kg) was administered to diet-induced obese mice once daily (Wargent et al. 2013). There was no significant change in the glycemic profile until after 3 weeks of administering high dose plant-derived THCV (12.5 mg/kg), where the once-daily administration of THCV resulted in a lower fasting glucose and the twice-daily administration of THCV resulted in increased glucose intolerance (Wargent et al. 2013). This suggests that THCV has a more profound leptin-based effect on the lipid profile than the glucose profile in both fasting and non-fasting states.
In CB1 knockout mice, rimonabant does not display the anti-obesity properties that were previously observed in diet-induced obese mice (Ravinet-Trillou et al. 2004). Like THCV, other synthetic cannabinoid antagonists such as O-4394 and O-4395 (Ravinet-Trillou et al. 2004; Englund et al. 2015), modulate the cannabinoid receptor activity. They showed similar physiologic activity, displacing the (3)-H-CP55940 in the mouse brain and antagonizing specific activity at the CB1 receptor sites in the brains of mice and vas deferens (CP55940 and R-(+)-WIN55212), respectively (Anavi-Goffer et al. 2012).
In a placebo-controlled, double-blind, cross-over pilot study involving ten male cannabis users (less than 25 uses/occasion), 10 mg pure THCV or placebo was given for 5 days followed by 1 mg intravenous THC infusion on the last day. When a low dose of oral THCV was administered before the THC intravenous dose, THCV blunted the well-known effects of THC including psychotic and paranoia effects, and impaired short-term memory (Englund et al. 2015).
In another randomised, double-blind, placebo-controlled, parallel-group pilot study, the safety and efficacy of THCV and CBD were evaluated in patients with type 2 diabetes using the glycemic and lipid parameters. Sixty-two patient volunteers with non-insulin treated type 2 diabetes were randomized to five treatment groups viz.: CBD (100 mg twice daily), THCV (5 mg twice daily), 1:1 ratio of CBD and THCV (5 mg/5 mg, twice daily), 20:1 ratio of CBD and THCV (100 mg/5 mg, twice daily) and matched placebo for 13 weeks. Patients were at least 18 years of age with hemoglobin A1C (HbA1C) levels less than 10% (Jadoon et al. 2016).
THCV significantly decreased fasting plasma glucose (from 7.4 to 6.7 mmol/L) compared to the placebo group which increased from 7.6 to 8 mmol/L 21 with an estimated treatment difference (ETD) of − 1.2 mmol//L, p < 0.05. It also improved the Homeostasis Model Assessment (HOMA2) of pancreatic β-cell function from 105.1 to 144.4 points compared to 96.4 to 94.7 points in the placebo group (ETD = 44.6 ± 16.1, p < 0.01) (Jadoon et al. 2016). Adiponectin is the protein hormone involved in regulating the plasma glucose levels and fatty acid breakdown (pancreatic function).